Mizoribine provides effective treatment of sequential histological change of arteritis and reduction of inflammatory cytokines and chemokines in an animal model of Kawasaki disease
<p>Abstract</p> <p>Background</p> <p>Intravenous immunoglobulin (IVIg) treatment results in an effective response from patients with acute-phase Kawasaki disease (KD), but 16.5% of them remain nonresponsive to IVIg. To address this therapeutic challenge, we tried a new...
Saved in:
Main Authors: | Ohno Naohito (Author), Nagi-Miura Noriko (Author), Yamada Hitomi (Author), Yokouchi Yuki (Author), Nagao Tomokazu (Author), Oharaseki Toshiaki (Author), Takahashi Kei (Author), Saji Tsutomu (Author), Okazaki Tomio (Author), Suzuki Kazuo (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2011-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Beneficial effects of anti-apolipoprotein A-2 on an animal model for coronary arteritis in Kawasaki disease
by: Fuyu Ito, et al.
Published: (2022) -
Chronopharmacology of Mizoribine in Collagen-Induced Arthritis Rats
by: Yuko Kanasaki, et al.
Published: (2012) -
Involvement of Multiple Transporters-mediated Transports in Mizoribine and Methotrexate Pharmacokinetics
by: Teruo Murakami, et al.
Published: (2012) -
Efficacy and safety of adding mizoribine to standard treatment in patients with immunoglobulin A nephropathy: A randomized controlled trial
by: Keiji Hirai, et al.
Published: (2017) -
Leukocyte activation by (1→3)-β-D glucans
by: Yoshiyuki Adachi, et al.
Published: (1997)